NASDAQ:NKTR

Nektar Therapeutics (NKTR) Stock Price, News & Analysis

Nektar Therapeutics logo
$36.18 -0.26 (-0.71%)
As of 02:19 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Nektar Therapeutics Stock (NASDAQ:NKTR)

Advanced

Key Stats

Today's Range
$35.41
▼
$36.50
50-Day Range
$35.78
▼
$75.44
52-Week Range
$33.40
▼
$109.00
Volume
270,055 shs
Average Volume
1.06 million shs
Market Capitalization
$1.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$130.33
Consensus Rating
Moderate Buy

Company Overview

Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases.

Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine.

Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work. Its research has included polymer-conjugation technologies intended to improve the properties of medicines.

AI Generated. May Contain Errors.

Nektar Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

NKTR MarketRank™: 
2.564374834085 of 5 stars

Nektar Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 512th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nektar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 1 strong buy rating, 10 buy ratings, 4 hold ratings, and 1 sell rating.

  • Upside Potential

    Nektar Therapeutics has a consensus price target of $130.33, representing about 265.3% upside from its current price of $35.68.

  • Amount of Analyst Coverage

    Nektar Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Nektar Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Nektar Therapeutics are expected to decrease in the coming year, from ($8.08) to ($11.07) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nektar Therapeutics is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nektar Therapeutics is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nektar Therapeutics has a P/B Ratio of 8.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    20.33% of the float of Nektar Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Nektar Therapeutics has a short interest ratio ("days to cover") of 10.26, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Nektar Therapeutics has recently decreased by 3.31%, indicating that investor sentiment is improving.
  • Dividend Yield

    Nektar Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Nektar Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Nektar Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Nektar Therapeutics this week, compared to 10 articles on an average week.
  • Search Interest

    Only 5 people have searched for NKTR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,476.00 in company stock.

  • Percentage Held by Insiders

    2.50% of the stock of Nektar Therapeutics is held by insiders.

  • Percentage Held by Institutions

    75.88% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nektar Therapeutics' insider trading history.
Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NKTR Stock News Headlines

Nektar Therapeutics Earnings Call Signals Clinical Momentum
I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
Oppenheimer Remains a Buy on Nektar Therapeutics (NKTR)
Piper Sandler Keeps Their Buy Rating on Nektar Therapeutics (NKTR)
Nektar Therapeutics (NASDAQ:NKTR) Stock Moved Down to Sell by Wall Street Zen
Nektar (NKTR) Q3 2026 Earnings Call Transcript
See More Headlines

NKTR Stock Analysis - Frequently Asked Questions

Nektar Therapeutics' stock was trading at $42.28 at the beginning of the year. Since then, NKTR stock has decreased by 15.6% and is now trading at $35.6820.

Nektar Therapeutics (NASDAQ:NKTR) posted its quarterly earnings data on Thursday, November, 12th. The biopharmaceutical company reported ($1.63) EPS for the quarter, beating the consensus estimate of ($2.07) by $0.44. The biopharmaceutical company had revenue of $9.39 million for the quarter, compared to analysts' expectations of $10.27 million. Nektar Therapeutics had a negative net margin of 339.67% and a negative trailing twelve-month return on equity of 33.89%.
Read the conference call transcript
.

Nektar Therapeutics shares reverse split on Monday, June 9th 2025.A 1-15 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, June 8th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Nektar Therapeutics' top institutional shareholders include Two Seas Capital LP (9.80%), State Street Corp (5.19%), Goldman Sachs Group Inc. (1.82%) and K2 Principal Fund L.P. (0.31%). Insiders that own company stock include Deep Track Capital, Lp, Howard W Robin, Mark Andrew Wilson, Robert Chess and Jonathan Zalevsky.
View institutional ownership trends
.

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nektar Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Bristol Myers Squibb (BMY), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Block (XYZ).

Company Calendar

Last Earnings
11/12/2026
Today
11/17/2026
UBS Global Biopharma Conference 2026
11/17/2026
Jefferies Global Healthcare Conference
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:NKTR
CIK
906709
Employees
63
Year Founded
1990

Price Target and Rating

High Price Target
$192.00
Low Price Target
$50.00
Potential Upside/Downside
+260.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($6.46)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$164.08 million
Net Margins
-339.67%
Pretax Margin
-280.48%
Return on Equity
-33.89%
Return on Assets
-24.86%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.42
Quick Ratio
10.42

Sales & Book Value

Annual Sales
$55.23 million
Price / Sales
22.38
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.41 per share
Price / Book
8.21

Miscellaneous

Outstanding Shares
34,140,000
Free Float
33,289,000
Market Cap
$1.24 billion
Optionable
Optionable
Beta
1.44

Social Links

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:NKTR) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners